Anti-mesothelin Antibody-drug Conjugate SGN-MesoC2

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of a human monoclonal antibody directed against the cell surface glycoprotein and tumor-associated antigen (TAA) mesothelin (MSLN) and conjugated, via a tumor-specific cleavable linker, to a topoisomerase-1 inhibitor (TOP1i), with potential antineoplastic activity. Upon administration of anti-MSLN ADC SGN-MesoC2, the monoclonal antibody moiety targets and binds to MSLN-expressing tumor cells. Upon binding, internalization and linker cleavage, the TOP1i is released, and inhibits DNA topoisomerase-1 activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of MSLN-expressing tumor cells. MSLN is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue.

**Synonyms:** - ADC SGN-MesoC2 - Anti-MSLN ADC HBM9033 - Anti-MSLN ADC SGN-MesoC2 - Anti-MSLN/TOP1i ADC SGN-MesoC2 - HBM 9033 - HBM-9033 - HBM9033 - PF 08052666 - PF-08052666 - PF08052666 - SGN MesoC2 - SGN-MesoC2 - SGNMesoC2 - YL 215 - YL-215 - YL215